4-fluoro-6-methyl-1-[1-tetrahydro-2H-pyran-4-yl-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one | 932373-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-fluoro-6-methyl-1-[1-tetrahydro-2H-pyran-4-yl-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one
• 英文别名: 7-fluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one；GSK1034702；4-fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one；4-Fluoro-6-methyl-1-(1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one
• CAS: 932373-87-0
• 化学式: C₁₈H₂₄FN₃O₂
• 分子量: 333.406
• InChiKey: KRRSQJOVDWYKHH-UHFFFAOYSA-N

物化性质

• 密度：
  1.258±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  4

制备方法与用途

GSK1034702是一种M1 mAChR变构激动剂，显示出对啮齿动物的促认作用。在认知功能障碍的尼古丁戒断模型中，GSK1034702能够调节海马功能，从而改善记忆编码。

反应信息

• 作为反应物：
  描述：

  4-fluoro-6-methyl-1-[1-tetrahydro-2H-pyran-4-yl-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one 在 柠檬酸 作用下， 以 乙腈 为溶剂， 反应 96.0h， 以64%的产率得到4-fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one monocitrate
  参考文献：
  名称：

  WO2007/36715

  摘要：

  公开号：
• 作为产物：
  描述：

  (2-amino-3-fluoro-5-methylphenyl)[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]amine 在 Carbonyldiimidazole 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 4-fluoro-6-methyl-1-[1-tetrahydro-2H-pyran-4-yl-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  WO2007/36715

  摘要：

  公开号：

文献信息

• Palladium-mediated oxidative carbonylation reactions for the synthesis of¹¹C-radiolabelled ureas
  作者：Steven Kealey、Stephen M. Husbands、Idriss Bennacef、Antony D. Gee、Jan Passchier

  DOI：10.1002/jlcr.3151

  日期：2014.4

  Palladium(II)-mediated oxidative carbonylation reactions have been used to synthesize 11C-radiolabelled ureas via the coupling of amines with [11C]carbon monoxide, in a one-pot process. Following trapping of 11CO in a solution of copper(I) tris(3,5-dimethylpyrazolyl)borate, homocoupling reactions of primary aliphatic amines proceed in the presence of Pd(PPh3)2Cl2 to give the corresponding N,N-disubstituted [11C]ureas. Secondary amines do not produce the corresponding N,N,N,N-tetrasubsituted [11C]ureas under these conditions. This difference in reactivity allows for the formation of unsymmetrical N,N’,N’-trisubstituted [11C]ureas using a mixture of a primary amine and a reactive secondary amine. The potential use of this method in positron emission tomography (PET) was demonstrated by the synthesis of the M1 muscarinic acetylcholine receptor radiotracer, [11C-carbonyl]GSK1034702.

  钯(II)介导的氧化羰基化反应已被用于通过将胺与[11C]一氧化碳耦合，在一步法中合成11C放射性标记的脲类化合物。在将11CO捕获在铜(I)三(3,5-二甲基吡唑)硼酸盐溶液后，初级脂肪胺的同源偶联反应在Pd(PPh3)2Cl2的存在下进行，生成相应的N,N-二取代[11C]脲。次级胺在这些条件下不产生相应的N,N,N,N-四取代[11C]脲。这种反应性差异使得可以利用初级胺与反应性较强的次级胺的混合物形成不对称的N,N’,N’-三取代[11C]脲。通过合成M1毒蕈碱型乙酰胆碱受体放射性示踪剂[11C-羰基]GSK1034702，展示了该方法在正电子发射断层成像（PET）中的潜在应用。
• Compounds which have activity at M1 receptor and their uses in medicine.
  申请人：Budzik Brian

  公开号：US20080058378A1

  公开（公告）日：2008-03-06

  Compounds of formula (I) and salts and solvates are provided: wherein R 4 is fluoro, R 5 is selected from hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 1-6 alkoxy, and C 1-6 alkoxy substituted with one or more fluorine atoms; and R 6 is selected from halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 3-6 cycloalkyl, C 3-6 cycloalkyl substituted with one or more fluorine atoms, C 1-6 alkoxy and C 1-6 alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C 1-6 alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

  提供了式(I)的化合物及其盐和溶剂化物： 其中R4为氟，R5选自氢、卤素、氰基、C1-6烷基、一种或多种氟原子取代的C1-6烷基、C1-6烷氧基和一种或多种氟原子取代的C1-6烷氧基；R6选自卤素、氰基、C1-6烷基、一种或多种氟原子取代的C1-6烷基、C3-6环烷基、一种或多种氟原子取代的C3-6环烷基、C1-6烷氧基和一种或多种氟原子取代的C1-6烷氧基，Q为氢或C1-6烷基。这些化合物预计在治疗方面有用，例如在治疗精神障碍和认知障碍方面。
• Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine
  申请人：Budzik Brian

  公开号：US20080255195A1

  公开（公告）日：2008-10-16

  Compounds of formula (I) and salts are provided: wherein R 4 is fluoro, R 5 is selected from hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 1-6 alkoxy, and C 1-6 alkoxy substituted with one or more fluorine atoms; and R 6 is selected from halogen, cyano, C 1-6 alkyl, C 1-6 alkyl substituted with one or more fluorine atoms, C 3-6 cycloalkyl, C 3-6 cycloalkyl substituted with one or more fluorine atoms, C 1-6 alkoxy and C 1-6 alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C 1-6 alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

  提供了化学式（I）和盐的化合物：其中R4为氟，R5从氢，卤素，氰基，C1-6烷基，C1-6烷基取代物，其中取代了一个或多个氟原子，C1-6烷氧基和C1-6烷氧基取代物中选择; R6从卤素，氰基，C1-6烷基，C1-6烷基取代物中选择，其中取代了一个或多个氟原子，C3-6环烷基，C3-6环烷基取代物中选择一个或多个氟原子，C1-6烷氧基和C1-6烷氧基取代物，Q为氢或C1-6烷基。预计这些化合物在治疗中会有用，例如在治疗精神障碍和认知障碍方面。
• Compounds which have activity at M1 receptor and their uses in medicine
  申请人：Glaxo Group Limited

  公开号：US08283364B2

  公开（公告）日：2012-10-09

  Compounds of formula (I) and salts are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

  提供了公式（I）和盐的化合物：其中R4为氟，R5选择自氢，卤素，氰基，C1-6烷基，C1-6烷基取代一个或多个氟原子，C1-6烷氧基和C1-6烷氧基取代一个或多个氟原子; R6选择自卤素，氰基，C1-6烷基，C1-6烷基取代一个或多个氟原子，C3-6环烷基，C3-6环烷基取代一个或多个氟原子，C1-6烷氧基和C1-6烷氧基取代一个或多个氟原子，Q为氢或C1-6烷基。这些化合物预计在治疗中有用，例如用于治疗精神障碍和认知障碍。
• MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM
  申请人：Chase Pharmaceuticals Corporation

  公开号：EP4019018A1

  公开（公告）日：2022-06-29

  A combination of a muscarinic cholinergic receptor agonist with a non-anticholinergic antiemetic agent, and the optional addition of an acetyl choline esterase inhibitor, for the treatment of hypocholinergic disorder of the central nervous system.

  一种毒蕈碱类胆碱能受体激动剂与非抗胆碱能止吐药的复方制剂，并可选择添加乙酰胆碱酯酶抑制剂，用于治疗中枢神经系统的低胆碱能紊乱。